NCT03271489 2025-07-22
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
Clinical Trials
7 trialsNCT03951077 2022-06-08
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
AbbVie
Phase 2 Completed
NCT03886220 2022-03-31
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 4 Completed
NCT02691494 2021-07-13
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
AbbVie
Phase 3 Completed
NCT02925494 2021-07-13
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
AbbVie
Phase 3 Completed
NCT01817530 2020-07-21
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
AbbVie
Phase 2 Completed
NCT02654054 2020-06-29
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed